A further consequence of this evidentiary asymmetry is the absence of mature overall survival benchmarks for IDH inhibitors, a limitation that fundamentally restricts their interpretability within the therapeutic landscape of oligodendroglioma. This evidence concerns the gene IDH2 and oligodendroglioma.